Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use.

Article Details

Citation

Gaitanis A, Staal S

Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use.

Methods Mol Biol. 2010;624:385-92. doi: 10.1007/978-1-60761-609-2_26.

PubMed ID
20217610 [ View in PubMed
]
Abstract

Liposomal doxorubicin and nab-paclitaxel are nanoparticle formulations of traditional cancer chemotherapy drugs which have ample clinical experience both pre- and post-nanoparticle modification. The alterations in pharmacokinetics, pharmacodynamics, efficacy, and toxicity compared with their parent compounds are instructive for future development of nanoparticle-based therapies. In this article we review the current status of these agents, emphasizing the alterations in clinical behavior resulting from the nanoparticle formulation of the parent compound.

DrugBank Data that Cites this Article

Drugs